{"analyses":[{"ciLowerLimit":"0.35","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.20","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.1327","paramType":"Risk Ratio (RR)","paramValue":"0.67","statisticalMethod":"exact binomial"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16"},{"groupId":"OG001","value":"0.24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"179"}],"units":"Participants"}],"description":"The on-treatment adverse event rate of infection requiring IV antibiotics, antifungals, or antivirals per patient-years. The on-treatment period was considered the period from the date of randomization to the last treatment study visit.","groups":[{"description":"Azacitidine, 75 mg/m\\^2/day given by subcutaneous injection for 7 days of every 28 day cycle, plus best supportive care.","id":"OG000","title":"Azacitidine"},{"description":"Physician choice of low dose cytarabine, standard chemotherapy, or best supportive care (consisting of blood products, growth factors, antibiotics)","id":"OG001","title":"Conventional Care"}],"paramType":"NUMBER","populationDescription":"Intent to treat population","reportingStatus":"POSTED","timeFrame":"Day 1 (randomization) to 42 months","title":"Number of Infections Per Treatment Year Requiring Intravenous Antibiotics, Antifungals or Antivirals","type":"SECONDARY","unitOfMeasure":"infections per treatment year"}